• Fresenius Medical Care refined its China commercial strategy to drive long-term growth via a more localized portfolio and tighter go-to-market focus.
• China plan shifts emphasis toward in-center dialysis and critical care, led by increased commercialization of locally relevant innovation.
• Production and sales of the 4008A hemodialysis system will be discontinued locally.
• China peritoneal dialysis business will be exited, with existing market obligations maintained.
• Portfolio actions are expected to trigger one-time costs of about EUR 110 million in Q3 2026, treated as a special item.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FMC - Fresenius Medical Care AG published the original content used to generate this news brief via PR Newswire (Ref. ID: NE56871) on September 25, 2026, and is solely responsible for the information contained therein.